Principal Financial Group Inc. acquired a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,790 shares of the company’s stock, valued at approximately $98,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Amalgamated Bank raised its holdings in Scholar Rock by 15.5% in the 4th quarter. Amalgamated Bank now owns 4,869 shares of the company’s stock valued at $92,000 after acquiring an additional 652 shares in the last quarter. DNB Asset Management AS raised its stake in shares of Scholar Rock by 28.5% in the second quarter. DNB Asset Management AS now owns 19,812 shares of the company’s stock valued at $165,000 after purchasing an additional 4,390 shares in the last quarter. Walleye Trading LLC bought a new position in Scholar Rock in the first quarter worth $178,000. Values First Advisors Inc. acquired a new stake in Scholar Rock during the second quarter worth $216,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Scholar Rock by 66.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 13,868 shares of the company’s stock valued at $246,000 after buying an additional 5,522 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.
Scholar Rock Trading Down 5.5 %
Shares of Scholar Rock stock opened at $8.10 on Tuesday. The stock has a market capitalization of $648.24 million, a P/E ratio of -3.88 and a beta of 0.82. Scholar Rock Holding Co. has a 12-month low of $5.94 and a 12-month high of $21.17. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.36. The company has a 50-day simple moving average of $8.92 and a 200 day simple moving average of $11.45.
Analyst Ratings Changes
A number of equities analysts have recently commented on the stock. BMO Capital Markets raised their price objective on shares of Scholar Rock from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Wedbush restated an “outperform” rating and set a $23.00 price target on shares of Scholar Rock in a research note on Thursday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Scholar Rock in a research note on Tuesday, June 25th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $26.43.
View Our Latest Stock Analysis on SRRK
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
See Also
- Five stocks we like better than Scholar Rock
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- What is a Stock Market Index and How Do You Use Them?
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- With Risk Tolerance, One Size Does Not Fit All
- 5 Oversold Stocks to Buy Right Now
Want to see what other hedge funds are holding SRRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report).
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.